MSK and OpenEvidence announce two-way oncology AI integration

Memorial Sloan Kettering and OpenEvidence announced a partnership: the OpenEvidence platform will be embedded in MSK's Epic system, while the OncoKB knowledge base will be integrated into OpenEvidence for physicians across the US. OncoKB covers more than 5,600 genetic alterations in 680+ genes and has partial FDA recognition.

• OpenEvidence integrates into MSK's Epic system for bedside decision support
• OncoKB is embedded in OpenEvidence for physicians outside MSK
• OncoKB covers 5,600+ genetic alterations in 680+ genes
• The FDA granted OncoKB partial recognition in 2021